Areva Med is an AREVA subsidiary working on the research against the cancer. By developing innovative processes to produce lead-212, Areva Med contributes to the fight against the cancer. This rare isotope offers promising perspectives to fight, notably, ovarian, pancreatic, colon, prostate, breast and other cancers. Areva Med has two missions: Industrialize the production of the lead-212 and Develop effective therapies to fight the cancer. The treatment by alpha radioimmunotherapy shows great potential to fight certain fatal diseases like breast, ovarian, pancreatic, prostate and colon cancer. The medical subsidiary of AREVA leads experiments to extract rare isotope through its Research and Development programs.